Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Lymphoma
- Interventions
- Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT05189093
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciense, Beijing, Beijing, China
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Waterstone Hanxbio Pty Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT04886271
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Waterstone Hanxbio Pty Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT04097769
- Locations
- 🇦🇺
St George Private Hospital, Kogarah, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath